Profile

Established in the year 1984, Morepen Laboratories is a fast growing Pharmaceutical company listed in all major stock exchanges in India including Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) since 1993 with an Investor base of 62,400 shareholders. Top-notch financial institutions of the country like UTI, LIC and GIC are its investors since IPO. The company has an asset base of over USD 286 million and growing.

Today Morepen has steadily grown from a Single product company to a Multi activity company with a global vision and satisfied customers in over 50 countries. It has resources of international standing; USFDA approved manufacturing facility for API at Masulkhana (Himachal Pradesh), adhering to the most stringent standards of quality excellence. In addition to this state-of-the-art finished dosage and API plants at Parwanoo and Baddi (Himachal Pradesh) have the latest cGMP guidelines, and their Quality Systems, Technical Product Information and Documentation processes etc., are in perfect line to meet the regulatory requirements for Exports to various countries.

Morepen has a progressive lineage of manufacturing high quality Generic drugs and Pharmaceutical formulations backed by a strong R&D, Regulatory and global marketing team. The big thrust of Morepen’s strategy is, focused on creating a new category in the Indian International pharmaceutical market vis a vis, Pharma Contract Manufacturing. Morepen aims to provide sufficient visibility to its products and direct its business portfolio to the high value DMFs and ANDA driven International Export Business. Apart from leveraging its traditional strength in APIs, the Company is now concentrating on finished formulations in both regulated and non-regulated markets.

Morepen today is the largest producer of Loratadine in the World and presently has, over 90% market share of generic Loratadine in the US market other than the Innovator by supplying the bulk drug to top class customers like Novartis, Merck etc. Morepen is the approved global supplier to these companies. By successfully complying with USFDA standards, Morepen has further cleared the decks for other product entries in the world market. While catering to a growing list of customers across regulatory markets in the US, Canada, Europe etc, Morepen has already successfully introduced new products like Atorvastatin, Fluvastatin, Montelukast and Fexofenadine, while in the R&D pipeline are products like Pioglitazone, Moxifloxacin and Gatifloxacin. Exports of these molecules have contributed 75-80% of Morepen's turnover in the last three quarters.

Morepen is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs for new APIs and respective ANDAs for finished dosages. Morepen plans to fill the niche as a global pharma contract manufacturing source by offering select finished dosage forms with its ANDAs via contract manufacturing to major global players in regulated markets. This is a highly focused and dynamic business model that allows Morepen to optimize its core competencies and also allows focus on products that have synergies with respect to the Company’s current chemistry skills. The R&D center at Masulkhana, Parwanoo and Baddi is well equipped and hi-technology based with over 40 scientists working on various projects primarily for new innovative non-infringing processes and development of cost effective proprietary technologies. The company has filed 14 patents in last three years including 6 international PCT applications. Morepen has recently filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world.

Morepen has also tied up with DrugMax Inc of USA to form Morepenmax. Following the formation, Morepen will convert its high value bulk drugs to dosage forms for further value addition and would also outsource blockbuster drugs to manufacture dosage forms for US Market. MorepenMax also has plans to file ANDA for few of its drugs.

At its new finished formulations & API facility at Baddi (HP) preparations are underway for seeking USFDA approval. The company is planning to manufacture three anti-hypertensive drugs at this facility. These drugs, Benazepril, Lisinopril and Ramipril are collectively valued at $2.83 billion. Capitalizing on the recently, USFDA approved infrastructure at Masulkhana; Morepen has added two more products to the same facility. These two molecules Citalopram and Sertraline are anti-depressant drugs that command a combined market size of $4.25 billion. Their Drug Master Files (DMFs) are expected to be filed in the next 6 months.

The strategy is to focus on a few lifestyles therapeutic segments such as Cardiovascular, Diabetes, Neuropsychiatry, Asthma and Allergies and a few other select categories. All these categories are large and growing and they represent lifestyle chronic diseases that have long-term treatment therapies. A number of molecules are going off patent in the next few years in these segments.

On the domestic side, Morepen has a large distribution base all over India, with company warehouses in all states and strong Sales and Marketing teams with more than 300 experienced people. Morepen associates with app. 80000 doctors and over 100000 pharmacies for its pharmaceutical products and has presence in over 200,000 retail outlets for its Health products (OTC). Morepen was the first company to emphasize the need for Self-health in the country and thus created a brand "Dr. Morepen". Morepen also has tie-ups with several international diagnostics giants like Beurer of Germany, Diamed AG of Switzerland, Hemocue of Sweden & Menarini of Italy for exclusive marketing and servicing in India. Morepen had also acquired two brands and a chain of Health and Beauty stores- Lifespring. Expansion plans for opening new stores is on with a clear strategy to be present in every locality.

Board of Directors | Company Audio-Visual